Noxopharm Limited

NOX

AU000000NOX9

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 08:22:23 27/06/2024 am IST			5-day change	1st Jan Change
0.068 ^AUD	-1.45%		-2.86%	-4.23%

28/05	Noxopharm Joins Alliance for mRNA Medicines; Shares Up Nearly 7%	MT
04/04	Noxopharm Receives AU$100,000 to Progress Brain Cancer Drug	MT

357,500 options of Noxopharm Limited are subject to a Lock-Up Agreement Ending on 8-JAN-2017.

January 08, 2017

357,500 options of Noxopharm Limited are subject to a Lock-Up Agreement Ending on 8-JAN-2017. These options will be under lockup for 153 days starting from 8-AUG-2016 to 8-JAN-2017.

Latest news about Noxopharm Limited

Noxopharm Joins Alliance for mRNA Medicines; Shares Up Nearly 7%	28/05	MT
Noxopharm Receives AU$100,000 to Progress Brain Cancer Drug	04/04	MT
Noxopharm Narrows Fiscal H1 Net Loss Despite Lower R&D Tax Incentive	27/02	MT
Noxopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023	27/02	CI
Noxopharm Extends Strategic Partnership with Hudson Institute of Medical Research	13/02	MT
Noxopharm Receives AU$6.1 Million R&D tax Rebate; Shares Up 8%	16/11	MT
Concerns of Further US Monetary Tightening Push Australian Shares to Nearly 11-Month Low	04/23/04	MT
US FDA Grants Orphan Drug Status to Noxopharm's Pancreatic Cancer Drug; Shares Surge 73%	04/23/04	MT
Noxopharm Validates Efficacy of Cancer Treatment in Animal Study; Shares Rally 13%	28/23/28	MT
Noxopharm Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/23/31	CI
NobleOak Life Secures Approval from Financial Services Regulator for Reporting Standards	03/23/03	MT
Noxopharm Limited Announces Change of Registered Office and Principal Place of Business	19/23/19	CI
Study Finds Noxopharm's New SOF-XX Drug Reduces Inflammation	19/23/19	MT
Noxopharm's NOXO Options to Expire June 18; Shares Down 17%	08/23/08	MT
Noxopharm to Discontinue Veyonda Trials; to Focus on Chroma, Sofra Platforms; Shares Plummet 41%	06/23/06	MT
Noxopharm to Develop Vaccine Enhancer; Shares Rise 3%	28/23/28	MT
Noxopharm Limited Announces Novel mRNA Vaccine Enhancer	28/23/28	CI
Noxopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2022	24/23/24	CI
Noxopharm Limited to Present Sofra Study at Lupus 2023 Conference	22/23/22	CI
NobleOak Life to Release Shares from Voluntary Escrow	09/23/09	MT
Noxopharm Advances to the Efficacy Portion of its Phase 2 Prostate Cancer Trial	17/23/17	MT
Noxopharm Limited Reviews Safety Data from the Third Cohort of Patients from the Dose Escalation Part of the DARRT-2 Trial	17/23/17	CI
Noxopharm's Strategic Partner Secures Grant Funding from the Australian Government	16/22/16	MT
Noxopharm Receives Innovation Connections Grant; Shares Fall 5%	06/22/06	MT
Noxopharm Limited Announces Award of Federal Innovation Connections Grant	06/22/06	CI

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.

Sector

Biotechnology & Medical Research

Calendar

29/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NOXOPHARM LIMITED	-4.23%	13.41M
MODERNA, INC.	+23.13%	46.93B
LONZA GROUP AG	+37.09%	39.08B
IQVIA HOLDINGS INC.	-8.73%	38.48B
ALNYLAM PHARMACEUTICALS, INC.	+28.09%	31.01B
CELLTRION, INC.	-12.26%	26.14B
ICON PUBLIC LIMITED COMPANY	+10.57%	25.88B
UNITED THERAPEUTICS CORPORATION	+45.05%	14.15B
MEDPACE HOLDINGS, INC.	+32.23%	12.53B
BIO-TECHNE CORPORATION	-6.56%	11.36B